Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study—IL PSO (Italian landscape psoriasis)

IntroductionBrodalumab is a monoclonal antibody that targets the subunit A of the interleukin-17A receptor (IL17RA), inhibiting the signaling of various isoforms of the IL-17 family. It has been approved for the treatment of moderate-to-severe plaque psoriasis after being evaluated in three Phase-3...

Description complète

Détails bibliographiques

Auteurs principaux:	Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, Fabrizio Amoruso, Giuseppe Argenziano, Anna Balato, Federico Bardazzi, Martina Burlando, Carlo Giovanni Carrera, Giovanni Damiani, Paolo Dapavo, Valentina Dini, Gabriella Fabbrocini, Chiara Franchi, Francesca Maria Gaiani, Giampiero Girolomoni, Claudio Guarneri, Claudia Lasagni, Francesco Loconsole, Angelo Valerio Marzano, Matteo Megna, Francesca Sampogna, Massimo Travaglini, Antonio Costanzo, Alessandra Narcisi
Format:	Artigo
Langue:	Inglês
Publié:	Frontiers Media S.A. 2023-07-01
Collection:	Frontiers in Medicine
Sujets:	brodalumab psoriasis psoriasis treatment psoriatic arthritis real-life
Accès en ligne:	https://www.frontiersin.org/articles/10.3389/fmed.2023.1196966/full
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!